|
مقاله
|
Abstract
|
|
|
|
Title:
|
Intravitreal Bevacizumab for the Treatment of Chronic Central Serous Chorioretinopathy
|
|
Author(s):
|
Aliagha Alishiri, Abolfazl Neishabouri, Seyed Aliasghar Mosavi
|
|
Presentation Type:
|
Poster
|
|
Subject:
|
Posterior Segment and Uveitis
|
|
Others:
|
|
|
Presenting Author:
|
|
|
Name:
|
Ali agha Alishiri
|
|
Affiliation :(optional)
|
Department of Ophthalmology, Baqiyatallah University of Medical Sciences , Tehran, Iran
|
|
E mail:
|
alishiri20002000@yahoo.com
|
|
Phone:
|
22093596
|
|
Mobile:
|
09171815137
|
|
|
|
|
Purpose:
|
To evaluate the efficacy of intavitreal injection of bevacizumab in patients with chronic central serous chorioretinopathy.
|
|
Methods:
|
In a clinical interventional case series , 22 patients with not-resolved central serous choroidoretinopathy (CSC) lasting more than 3 months received intravitreal bevacizumab injection (IVB, 1.25 mg) injection. All patients underwent a through ophthalmic examination 1 day, 1 week, and 1, 2 months after the injection. The visual acuity,central macular thickness , Subretinal space volume(SSV) and Contrast sensitivity were compared before and after treatment.
|
|
Results:
|
Mean best corrected visual acuity (BCVA) was improved significantly (p = 0.000) , Central macular thickness and Subretinal space volume was decreased significantly (p = 0.000)and Contrast sensitivity was increased significantly (p = 0.000) at last follow-up .
|
|
Conclusion:
|
Intravitreal bevacizumab can be an alternative treatment in patients with chronic central serous chorioretinopathy as it leads to a better objective visual acuity, contrast sensitivity and foveal thickness.
|
|
Attachment:
|
4229alishiri.pptx
|
|